Blogs of Professor(Dr.) Pranab Kumar Bhattacharyya MD(calcutta.Univ) Pathology;

Blogson TheoreticalPhysics;Astronomy; MedicalSciences,Pathology; etc.All contents,words, Syllables &;Scientificallymeaning ful sentences of all blogsposted are Strictly Copy Righted material to ProfDr Pranab Kumar Bhattacharya under IPR Copy Right Acts sections-306/301/3D/107/1012/ RDF and Protect Intellectual Property Right ACT of USA-2012. Don't try to infringe, to avoid huge civil/criminal proceedings in IPR Court: Acknowledgement for all my blogs to my Spouse Mrs Sumita Bhattacharya

Friday, 18 December 2015

A name of Exoplanets( Exo world) as "Dragon Planet "Suggested By Professor Dr Pranab Kumar Bhattacharya Accepted by IAU on 15th december 2015

Professor Dr Pranab kr Bhattacharya named an exo planet as "Dragon planet" in the Star " Iota Draconis" on 12 th august 2015 through URL [To vote, go to the Name ExoWorlds site here: http://nameexoworlds.iau.org/exoworldsvote] [http://www.space.com/30232-exoplanet-naming-contest-iau.html] and the name Dragon planet has now been accepted by International Astronomical Union USA rather for the constellation star formalhaut B and this "Dragon Planet" was as per his late mother late Mrs Bani. Bhattacharya (1935-2006) who believed in exo planets, life in other planet of distant solar system and she used to point a star she named it as *Dragon star*
visit URL
https://www.newscientist.com/article/dn16033-first-images-captured-of-alien-solar-system
http://nameexoworlds.iau.org/systems/103
http://nameexoworlds.iau.org/exoworldsvote
http://nameexoworlds.iau.org/names
http://www.iau.org/public/images/detail/iau1514a/
http://www.space.com/30232-exoplanet-naming-contest-iau.html
He voted on 12th august 2015 , going through URL to the NameExoWorlds site here: http://nameexoworlds.iau.org/exoworldsvote
Dagon
Dagon, an ancient Syrian “fish god” should be the name of the exo planet orbiting the bright star Fomalhaut (alpha Piscis Austrini) for many reasons. This system resides in, Piscis Australis, or the “Southern Fish”, so it’s only natural to associate a fish deity with this constellation and it is consistent with the current naming of planets as gods from various pantheons. The name Fomalhaut is Arabic for “Fish’s mouth”, further strengthening the fish theme.

In addition to these historical considerations, Dagon has also been used (and recreated) in the 20th century literature of H. P. Lovecraft in his short story “Dagon” (1919) with reference to an “ancient Philistine legend of Dagon, the Fish-God”. A further connection can be traced to a subsequent story written by a purveyor of the Lovecraftian mythos, August Derleth, who wrote “The Dweller in the Darkness” (1944) that features Fomalhaut as the home of beings that assist the protagonists.

Naming the exoplanet Dagon would both honor the established tradition of using mythological deities and possibly establish a doorway to using fictitious god or god-like names in the future. Dagon would also be a posthumous nod to H. P Lovecraft who always strived to write about “cosmic wonder”.
The name was proposed by Professor Pranab Kumar Bhattacharya of Kolkata, India for another constellation Star Draconis in memory of his late mother but accepted for constellation Formalhautb
We’d like to show the name‘Leisurely Fish’ for the companion star of Fomalhaut belonging to PsA. The reason why we say it leisurely is that the star moves very slowly. In addition, there is a word ‘fish’ in the name because it belongs to PsA. With the faster and faster speed of modern life, we forget to slow down to enjoy our life. So we want to use the name to remind everyone of slowing down to enjoy the beautiful night sky just as a leisurely fish. Thanks to Professor Bhattacharya

Please note it very carefully that, The Copy Right of this article belongs only
to Professor Pranab kumarBhattacharya MD(cal) FIC path(Ind) and other authors

in chronological order , as per copy right rules of IPR 1996 applicable in India-2006
under sections 307/ 306/ 3D/107/2012 and PIP Acts of US 2012, SPARC authors amended
Copy Right rules-2006 of US when & if accepted for any other blogs, as a reference, or publication or Research or reference material or published as paper or article in open access journals as a commissioned article and then also this article will be under RDF Copy Right rules of
IPR of Prof PK Bhattacharya.

No persons/ nor any Private care Hospitals/ nor any Nursing homes/ and their health care
provider doctors nurses paramedical staffs from any states of country India or any citizen of India or of Indian origin are for ever authorized by Professor Pranab kumar Bhattacharya to use any scientifically meaningful syllables/words /sentences/ new drugs/protocolos/ change of Health care by implementation from this published blog article in the Blogs of Prof Pranab kumar Bhattacharya MD(cal) FIC path(ind.) in Blog spot.com without his / future copy right owner ‘s written permission &copy Right clearance, even for any

one’s personal or for his/her fair use even/ treatment of his or her patients/ dissemination of

any information( Will be considered then as Plagiarism) , [except such all permission is always

remain granted to other authors ,their first degree blood relatives in what ever manner they want

to use this article for ever from the date of publication in ProfPranab Kumars Bhattacharya

MD(cal) FIC path(ind) Blog at blog spot.com or for digital preservation of the article in National

Level Science Library(NSDL) US or of other countries.- by declaration-

SD/ Professor Pranab kumar Bhattachary

Monday, 14 December 2015

Indian National Science Academy -

Senior Scientist award in 1987
P K Bbhattacharya

Monday, 30 November 2015

The Possible Future Treatment of Sickle cell anaemia republished in geneticdisorders.info

The Possible Future Treatment of Sickle cell anemia"

Source: "The Possible Future Treatment of Sickle cell anemia" Tag: sickle cell anemia pathophysiology at
geneticdisorders.info

Authors;
* Professor Pranab Kumar Bhattacharya MD(cal) FIC path(Ind)- Professor and Head,* Miss Upasana Bhattacharya- daughter of Prof.PK Bhattacharya ** Mr. Rupak Bhattacharya Bsc(cal) MSc(JU),** Mr Ritwik Bhattacharya B.com(cal); **Miss Rupsa Bhattacharya** Mr .Soumak Bhattacharya BHM, MSc-student(PUSHA) New Delhi;All of Residence- 7/51 Purbapalli, Sodepur, Dist 24 parganas(north) kol-110, ***Oindrila Mukherjee*** Mrs. Dalia Mukherjee BA(Hons) cal;*** Mr Debasis Mukherjee Bsc(cal). Dr. Ranu Roy Biswas MD(cal) Asst Professor. *Dr. Anuradha De DCP(cal) MD(AIIMS) Associate Professor; *Dr. Soma Das MBBS(cal) DCH(cal) Demonstrator; **

· Affiliation-*   Department of Pathology , Calcutta School of Tropical Medicine, CR Avenue ,Kol-73; W.B; India ** 7/51 Purbapalli, Po-Sodepur; Dist 24 pargnas( West Bengal) Kol-20*** Swamijinagar, South Habra, 24 Parganas(north) West Bengal.

Scientists have learned a great deal about sickle cell anaemia during the past 30 years - what causes it, how it affects the patient, and how to treat some of its complications. They also have begun to have success in developing drugs that will prevent the symptoms of sickle cell anaemia and procedures that should ultimately provide a possible cure.
Some researchers are focusing on identifying drugs that will increase the level of fetal hemoglobin in the blood. studies have shown that these people have less severe cases of the disease. Fetal hemoglobin seems to prevent
sickling of red cells, and cells containing fetal hemoglobin tend to  survive longer in the bloodstream.
Hydroxyurea appears to work primarily by stimulating production of fetal hemoglobin. There is some evidence that administering hydroxyurea with erythropoietin, a genetically engineered hormone that stimulates red cell
production, may make hydroxyurea work more better. This combination approach offers the possibility that lower doses of hydroxyurea can be  used to achieve the needed level of fetal haemoglobin to reduce side effects of both toxic drugs to search for safer agents that are just as effective.'Butyrate,- a simple fatty acid tha is widely used as a food additive, is
also being investigated as an agent that may increase fetal hemoglobin production. Clotrimazole, an over-the-counter medication commonly used to treat fungal infections, is under investigation as a treatment to prevent the loss of

water from RBC that contributes to sickling. Bone marrow transplantation has been shown to provide a cure for severely affected children with sickle cell disease. Researchers are working on techniques to f urther reduce some of the risks of bone marrow transplantation for patients with sickle cell disease. The ultimate cure for sickle cell anemia may be gene therapy. Gene therapy offers enormous promise as a potential curative therapy for SCD, but concerns over the safety of random genomic insertion must first be resolved . Pre-clinical studies in mice have provided the proof of principle that transduction of bone marrow stem cells with lentiviral vectors that express a beta-globin gene can prevent Hb S polymerization in vivo. The wide range of abnormalities engendered by the sickle cell mutation offers several other opportunities for therapeutic interventions. For example, the NIH Road Map is supporting ongoing investigations in which high-through put screening approaches are used to discover novel low -molecular-weight compounds that can alter key aspects of the disease, I ncluding hemoglobin polymerization, expression of Hb F, and leukocyte adhesion. Current clinical trials are evaluating the efficacy of Ca2+- sensitive Gardos channel inhibitors , with or without hydroxyurea, in preventing dehydration of erythrocytes . Vasoactive drugs (e.g., NO, sildenafil, endothelin antagonists) are being evaluated for the treatment i f pulmonary hypertension. Statins are of potentially great interest since they can increase NO production and reduce leukocyte adhesion . Selective antagonists & Intravenous gammaglobulins are currently under clinical evaluation following a study demonstrating a dose-dependent reduction in leukocyte adhesion and in the number of interactions between rbc and wbc, accompanied by improvements inmicrocirculatory blood flow and survival of sickle transgenic mice . Almost a century after SCD was first

described, we may be towards the dawn of a new era in which a physician one day might be able to use genetic information to select one or more drugs that target specific aspects of disease pathophysiology that are
relevant to a particular patient with SCD

Copy Right- Copy Right of this article belongs to Professor Pranab kumar Bhattacharya and his first degree relatives only as per copy right act & rules of Intellectual Property Right Rules 3D/107/1201 a,b/ RDF Copy Right rules/ SPARC copy Right rules-2006/ and Protect intellectual Property Right(PIP) copy right rules of USA-2012.Please do not Infringe and be enough careful for your own safety if you are not direct Blood relation to prof Pranab Kumar Bhattacharya . No person, No NGOS [ except the authors& first degree relatives] in the state of West Bengal or in any states of India or in any abroad countries are authorized to use this article, with any meaning full, scientific sentences or with scientific and meaning full words laid out in this article either in the class room/ or in mass teaching programme including CME or in any form what so ever it is with any content of this article or while in writing any book or for his/her personal/ home use, or collective works or for any future Research or implementation as a policy matter or,[ except the authors ]or by Xeroxing and distributing the article/ or by printing/saving/broadcasting the article from any website of internet services,displayed without proper copy right clearance from the authors or from his family members or future copy right owner by written forms.

Cost-Effectiveness of Biologics in Early Rheumatoid Arthritis | Annals of Internal Medicine

Thursday, 29 October 2015

Search Results for professor_pranab_kumar_Bhattacharya | Files Download.info - Free Shared Files Search Engine

Thursday, 8 October 2015

The Nobel Prize for Physics- 2015 has been awarded for neutrino puzzles for the discovery of neutrino oscillations, which shows that neutrinos have mass The discovery led to the far-reaching conclusion that neutrinos, which for a long time were considered massless, must have some mass, however small

The Nobel Prize for Physics- 2015 has been awarded for neutrino puzzles that physicists had wrestled with for decades had been resolved. Compared to theoretical calculations of the number of neutrinos, up to two thirds of the neutrinos were missing in measurements performed onEarth and also that for the discovery of neutrino oscillations, which shows that neutrinos have mass The discovery led to the far-reaching conclusion that neutrinos, which for a long time were considered massless, must have some mass, however small.
Please readURL http://www.nobelprize.org/.../laureates/2015/press.html
and also the  advanced Report of the Royal Swedish Academy of Science in PDF for 2015 Nobel prize in Physics
                                                                                                                                                                                                                                      That the Neutrinos has mass was also published by us in various times as in the " Science Blog" as we told there "Neutrinos were also non-Zero mass particles according authors , though in standard teaching, it is mass less. There are broadly three (3) species of ‘Neutrinos”. I) Electron neutrinos 2) Muon neutrinos 3) tat neutrinos and 4th variety we say Missing Neutrinos. During first half of twentieth century, physicists were convinced that all stars including our Sun, shines by converting, deep in its interior, hydrogen into helium. According ,this theory, 4 hydrogen nuclei called protons (p) are changed within solar interior into a 4He nucleus, 02 anti-electrons (e+, positively charged electrons), and 02 elusive and mysterious ghostly particles called neutrinos . This process of nuclear conversion, believed responsible for sunshine and therefore for all life on Earth. Conversion process, which involves many different nuclear reactions, can be written schematically as: 4p→4He +2e+ +2ve —-[1] as Bhattacharya Rupak wrote it once in 1995. I.e, two neutrinos produced each time as the fusion reaction (1) within star. Since 4 protons are heavier than a helium nucleus, two positive electrons and two neutrinos, reaction (1) releases lot of energies to Sun, that ultimately reaches earth as sunlight. The reaction occurs very frequently. Neutrinos escape easily from Sun their energy does not appear as solar heat or sunlight in earth. Sometimes neutrinos are produced with relatively low energies and Sun gets lot of heat. Sometimes neutrinos are produced with higher energies and Sun gets less energy. Neutrinos have zero electric charge, interact very rarely with matter, – according to particle physic’s very high reference level textbook version of the standard model of particle physics – they are mass less. About 1000 billion neutrinos from Sun pass through your thumbnail every seconds, but you do not feel them because, they interact so rarely and so weakly with matter. Neutrinos are practically indestructible; almost nothing happens to them. For every hundred billions solar neutrinos passing through Earth every seconds, only about one interacts if at all with stuff of Earth is made. Because they interact so rarely, neutrinos can escape easily from solar interior, where they are created and bring direct information about solar fusion reactions to us on Earth. There are three known types of neutrinos already told. Nuclear fusion in Sun produces only neutrinos that are associated with electrons, the so-called electron neutrinos . The two other types of neutrinos, muon neutrinos and tau neutrinos , are produced, for example, in laboratory accelerators or in exploding stars, together with heavier versions of the electron, the particles muon and tau . But there are some missing neutrinos too. All accepted models in cosmology & in particle physics however accept that neutrinos are mass less or so. But some idea that neutrinos might have mass also was about 40 yearsold."

See at Science Blogs comment published titled "Faster Than a Speeding Photon: “Measurement of the neutrino velocity with the OPERA detector in the CNGS beam” Posted by Chad Orzel on September 24, 2011 and the published comment no 43 by Professor Pranab Kumar Bhattacharya on September 28, 2011 as it was titled "Tachyons is an mathematical Imaginary particle that may move faster then Photons (Light particles) in the universe and yet to be discovered"
click on Links http://scienceblogs.com/.../faster-than-a-speeding.../...
                                                                                                                                                          Please Read also in our published article " Tachyon- Faster than Light Particle Exist in Our Universe or an Imaginary Mathematical Particle" by authors Rupak Bhattacharya Pranab Kumar Bhattacharya, Upasana Bhattachary, Ritwik Bhattacharya,Rupsa Bhattacharya, Dalia Mukherjee, Oaindrila Mukherjee, Aiyshi Mukherjee, Hindole Banerjee,Arunava Das published at International Journal of Astronomy, Astrophysics and Space Science 2015; 2(3): 12-29 Published online May 10, 2015 (http://www.openscienceonline.com/journal/aass) where we authors clearly told that "...........There is till no confirmed mass evidences that neutrinos have a non zero mass particles............
(Bhattacharjee Rupak and Bhattacharya Pranab Kumar)..........see at Page Nos 15-16
Click also on The Guridian UK at URL http://www.theguardian.com/.../the-lay.../2011/sep/23/1... Published at journal Physics Org titled as" Fate of a Star supernovas and mechanism of explosion of supernovas" at physics org of American Physical Society as a published comment of an article "Rare radio supernova in nearby galaxy is nearest supernova in five years" Click on URL https://www.facebook.com/PhysicsToday/posts/10156136212620164
See at Face Book of nobelprize.org "Questions for David Gross" by Prof Pranab Kr Bhattacharya Click on URL https://www.facebook.com/.../questions.../401404001719...
Please See the Published articles on Blogs of Professor Pranab Kumar Bhattacharya at Google Blog.com under blog title : Where from mass came in the universe?- Did the mass originated from mass less particle in Higgs Field - A child like question & quest! Is it really So?" Click on URL https://www.facebook.com/PhysicsToday/posts/10156136212620164 or http://totallydrug-resistanttbemergesinindia.blogspot.in/...
See the article Methods of Evaluation and Extraction of Membership Functions--Review with a New Approach" by authors Dwijesh Dutta Majumder, Rupak Bhattacharyya, Supratim Mukherjee click on URL http://ieeexplore.ieee.org/xpl/articleDetails.jsp...
                                                                                                                                                      Published articles on Blogs of Professor Pranab Kumar Bhattacharya at Google Blog.com under blog title " A smaller particle then quarks-possible at all?" please click on URL http://totallydrug-resistanttbemergesinindia.blogspot.in/...
Published articles on Blogs of Professor Pranab Kumar Bhattacharya at Google Blog.com under blog title Where Went the Anti matter?http://totallydrug-resistanttbemergesinindia.blogspot.in/...

[Next Tuesday the Royal Swedish Academy of Sciences will announce the winner (or winners) of this year's Nobel Prize in Physics. AIP's Ben Stein predicts that Kent Ford and Vera Rubin will be honored for their discovery, derived from stellar velocities, that the Andromeda Galaxy contains much more mass than is present in its visible stars. Since Ford and Rubin's paper was published in 1970, additional lines of evidence, including observations by Ford and Rubin of other galaxies, have supported their discovery. Now the only plausible explanation is that galaxies and the space between them are pervaded by an unknown kind of "dark matter," whose interactions with itself and with normal matter are either through the gravitational force or very weak]
https://www.facebook.com/PhysicsToday/posts/10156136212620164

Physics Today

October 1 at 4:08am

Thursday, 1 October 2015

Can we protect the population from Dengue diseases by a recombinant live attenuated tetravalent dengue vaccine?

Rapid Responses Published in BMJ on 29 September 2015as Letter to Editor

Research News

Trial results raise hope for dengue fever vaccine

BMJ 2015; 350 doi: http://dx.doi.org/10.1136/bmj.h141 (Published 09 January 2015) Cite this as: BMJ 2015;350:h141
Authors

Professor Pranab Kumar Bhattacharya MD (Calcutta Univ) FIC Path(India) now Professor of Pathology at Murshidabad District Medical College, West Bengal Behrampore Station Road ; Behrampore Court Murshidabad District West Bengal India

Dr Sumana Mukherjee Assoc Prof Pathology School of Tropical Medicine Kolkata; Miss Upasana Bhattacharya; Mr Rupak Bhattacharya; Mr Ritwick Bhattacharya ; Miss Rupsa Bhattacharya; Mrs Dalia Mukherjee Miss Ayishi Mukherjee Mr Debasis Mukherjee Mr Hindole Banerjee of Residence 7/51 Purbapalli Po Sodepur Dist 24 Parganas West Bengal Kolkata-110 India

profpkbkr

Dengue is a mosquito (Ades aegypti) borne viral illness in the tropics and subtropics including in India. Approximately 350 million infections occur annually, of which 96 millions have clinical manifestations on infection with one of four serotypes (DENV 1,2,3.4) of the dengue virus. These may result in asymptomatic infections, mild non-specific viral flu-like illness, classic dengue (DHF), and severe dengue-manifested by plasma leakage, hemorrhage, hepatitis, renal failure, multi-organ failure and finally death. Severe dengue may also manifest with variant types of atypical signs [3] and symptoms, and when a second infection with different serotypes occurs, people are at increased risk of severe dengue.
The incidence of dengue is increasing globally and becoming endemic. Dengue is almost endemic throughout India. The incidence of Dengue in 2014 was 47,000 cases in China as of May 2015; Malaysia reported more cases compared with 2014, and as of June 2015 Brazil reported over a million suspected cases of Dengue. Resource poor health care systems as in India depend on simple to perform and easy to interpret laboratory tests for diagnosis. It is known that early diagnosis of DHF and DSS followed by supportive therapy reduces morbidity and mortality from Dengue. Thrombocytopenia, NS1 antigen IgM & IgG by immunochromatographic tests are the mainstay of diagnosis of Dengue infections in peripheral areas; most tertiary care laboratories have Mac Enzyme Linked immunosorbant Assay for qualitative and quantitative detection, and PCR based diagnostic modality are found in research laboratories and medical colleges of Kolkata metro cities. Ns1 has 30% positivity, becoming more positive when there is more viral load.
There is yet no available medicine or vaccine for treatment and protection against dengue fever. Prevention is protection from mosquito bites and vector control--ie, reducing A. aegypti larvae and pupae.
There is a tetravalent recombinant live attenuated Dengue vaccine (CYT-TDV) having CYD-1 through CYD-4 which requires 3 injections at 0, 6, and 12 months. The efficacy rate was 60.8 (95% CI) and in children 64.7% (95%CI 58.7-69.8). For serotype DNV-1 the efficacy rate was 50.3%, for serotype 2, 42.3%, serotype 3, 74% and serotype-4, 77.4%. This vaccine was tested in 20,869 children in Latin America, where dengue infection is epidemic in age group 9-16 years, during June 2011-March 2012. [1] During follow up for 2 years a total of 10,053 febrile episodes were reported, 8965 (89.2%) blood samples were collected within 5 days of fever and VCD was diagnosed only in 668 cases by Mac ELISA and RTPCR; efficacy was highest for DNEV-4 and lowest for DNV-2 and varied between countries tested in a phase 3 clinical trial. [1]
Adverse effects of CYT-TDV occurred in 121 children, including moderate asthma attacks, allergic urticaria after the 2nd injection, acute peripheral neuropathy after the 1st injection, viral meningitis, unspecified seizure. Efficacy of this vaccine in reducing hospitalization is 80.3% against severe dengue.
The dengue vaccine is facing numerous challenges, according to the authors.[1] Viable dengue vaccine must be capable of protecting against disease caused by any of the 4 serotypes. [2] Problems include the lack of a validated animal model of human dengue disease, [3] incomplete understanding of immunopathology, [4], the release of neutralizing antibodies assays, and cross reactivity among serotypes.
Now the questions remain can we protect our population fom Dengue diseases and can we reduce the population of patients with severe dengue with this CYT-TDV vaccine? Why the disparity in efficacy in antibody response and against the 4 serotypes?
References
1] Luis Villov, Gustavo Horacid. Dayan ; Jose Arrendondo Gurcia; Doris Maribel Revera etal “ Efficacy of a tetravalent Dengue vaccine in Children in Latim Ameria” N engl.j. med 2015; 372; 113-23
2] Professor Pranab Kumar Bhattacharya, Ritwik Bhattacharya, Rupak Bhattacharya Dahlia Mukherjee, UpasanaBhattacharya etal Plaque reduction neutralization test for dengue virus is more sensitive test but expensive Rapid Response Published BMJ 13 December 2009 of article Clinical Review Diagnosis and management of dengue http://www.bmj.com/content/339/bmj.b4338/rapid-responses
3] Professor DR. Pranab Kumar Bhattacharya, Dengue fever in Kolkata, West Bengal India with atypical presentations and its prevention Blogs of Professor(Dr.) Pranab Kumar Bhattacharyya MD(cal.Univ) Pathology; http://totallydrugresistanttbemergesinindia.blogspot.in/2013/04/dengue-f...

Competing interests: No competing interests

This article "Can we protect the population from Dengue diseases by a recombinant live attenuated tetravalent dengue vaccine?" published in this Blog ND In BMJ {link provided} is Strictly Copy Righted material to Prof.(Dr.) Pranab Kumar Bhattacharya under his Intellectual Property Right(IPR) Copy Right Acts under sections-306/3D/107/1012( a,) (b ) / RDF and Protect Intellectual Property Right ACT of USA-2012. Please do not ever try to infringe to avoid huge amount damage suit charge in several cores INR / or civil suit / or even criminal proceedings in IPR Courts of India or in any other courts of India Professor Bhattacharya will deem fit it so . Please do not try or take any sort of attempts to infringe any thing [ besides reading or liking or commenting or E mailing if any if you have ] or engaging yourself in kinds of plagiarism for yours own safety purpose from Plagiarism suit or infringement of Copy Right act suit . You are not ever permitted to reproduce any things from his/ their postings/ published articles/comments/blogs/posts or sharing in his Face book etc or even use for your's fair uses also or dissemination for others knowledge or teaching or public as per IPR acts and laws for ever.These terms are however will not beapplicable for Professor Dr Pranab Kumar Bhattacharya's only daughter miss Upasana Bhattacharya , other authors and to all his family members who can use these articles and postings in this Blog or his face book for their beneficiary acts in future or ever in manner they desire to use.